ALK-positive NSCLC arises when a chromosomal rearrangement fuses the ALK kinase gene to a partner gene, most commonly EML4, producing a constitutively active signaling protein that drives uncontrolled proliferation. Since the first ALK inhibitor, crizotinib, entered the clinic, a succession of increasingly potent tyrosine kinase inhibitors (TKIs) has transformed outcomes for these patients. The latest generation agent, lorlatinib, demonstrated durable benefit in the phase III CROWN study. Yet resistance remains an inevitability for many patients. ALK’s kinase domain is a mutable target, and sequential treatment with TKIs selects for compound mutations that no drug approved to date can fully suppress. Patients who progress on available TKIs have limited options, a gap the authors identify as the central motivation for an orthogonal therapeutic approach.

Targeted protein degradation offers such an approach. Rather than blocking an enzyme’s active site, degraders eliminate the target protein altogether, harnessing the ubiquitin-proteasome system that cells use for routine protein turnover. Two broad strategies exist. Proteolysis-targeting chimeras, or PROTACs, are large bifunctional molecules that physically tether a target protein to an E3 ubiquitin ligase. Molecular glue degraders, by contrast, are typically smaller, more drug-like compounds that bind the E3 ligase substrate receptor and remodel its surface to recognize a neosubstrate. Their smaller size confers potential advantages in oral bioavailability and tissue penetration, but discovering glues for a chosen target has historically been a matter of luck rather than design, because the interaction is not obvious from sequence alone.

The Triana team found TRI-611 through a deliberate engineering effort. Using a time-resolved fluorescence resonance energy transfer screen that reports when ALK and cereblon (CRBN), the substrate adaptor of the CRL4 ubiquitin ligase complex, are brought into proximity, the researchers identified an initial hit compound and then optimized it for potency, selectivity and drug-like properties. Structural and biophysical work, including cryo-electron microscopy of the ternary complex, revealed that TRI-611 operates through a distinctive mechanism. The glue promotes contact between the ALK kinase domain and CRBN through a degron interface positioned distal to the kinase active site. This arrangement matters for two reasons: the drug does not need to compete with ATP at a mutation-prone catalytic pocket, and its binding surface tolerates mutations that disable orthosteric inhibitors.

That structural feature translates directly into resistance coverage. In engineered cell lines and patient-derived models, TRI-611 degraded not only wild-type EML4-ALK but also versions carrying clinically important TKI-resistance mutations, including the gatekeeper mutation L1196M and the solvent-front mutation G1202R, individually and in combination. Biochemical assays demonstrated that the drug supported ubiquitin transfer onto the mutant kinase domain by the CRBN-containing ligase complex, and degradation potency correlated tightly with anti-proliferative activity across a panel of resistant lines. Proteomic profiling after TRI-611 treatment showed a remarkably clean footprint: among thousands of quantified proteins, ALK fusion proteins were selectively depleted, with minimal effects on known CRBN neosubstrates or other kinases. In an era when glue degraders are often criticized for promiscuous neosubstrate recruitment, that selectivity is a notable technical achievement.

The pharmacology was engineered with the brain in mind. ALK-positive NSCLC has a notorious tendency to metastasize to the central nervous system, and the blood-brain barrier excludes many otherwise effective drugs, making brain metastases a frequent site of progression. Guided by central nervous system multiparameter optimization principles, the team tuned the compound’s permeability and efflux properties. In mice, TRI-611 achieved brain-to-plasma exposure ratios comparable to lorlatinib, a benchmark for brain penetration, and unbound brain concentrations exceeded the levels needed for target degradation. Once-daily oral dosing produced regressions of subcutaneous xenografts derived from both cell lines and patients, including the DFCI-669 model and the MGH953-7 patient-derived model, the latter harboring TKI-resistance mutations. Critically, intracranial xenograft models, including one driven by the doubly resistant L1196M/G1202R mutant, also responded, with luminescence-based tumor measurements showing marked shrinkage in treated animals.

Perhaps the most clinically provocative finding concerns combination therapy. Because TRI-611 binds the kinase domain at a surface remote from the ATP pocket, it does not interfere with orthosteric TKIs, and the two modalities can be used together. In vitro, the combination of TRI-611 with alectinib or lorlatinib produced greater-than-additive killing of ALK-dependent cells, quantified by Bliss synergy analysis. In vivo, pairing the degrader with lorlatinib yielded synergistic and durable tumor regressions in subcutaneous and intracranial models, outperforming either agent alone. The logic is compelling: the TKI suppresses signaling immediately while the glue removes the protein irreversibly, and degrading the target may suppress the evolutionary escape routes that kinase inhibition alone leaves open. The combination also addresses a second resistance mechanism, MET amplification, which can bypass ALK entirely; pairing TRI-611 with a MET inhibitor such as capmatinib restored growth control in MET-overexpressing models.

The study is thorough on the mechanistic details that regulators and clinicians will want. Degradation required the proteasome, as shown by rescue experiments with bortezomib, and was enhanced by CRBN overexpression, confirming the ligase dependence of the effect. Treated tumors showed loss of phosphorylated STAT3, a downstream readout of ALK signaling, within hours of dosing, linking pharmacokinetics to pharmacodynamics. Structural biology pinned the molecular determinants: mutation of a key ALK residue in the degron interface, D1389W, abolished both degradation and the compound’s anti-proliferative effect, demonstrating that the observed binding mode is causally responsible for the biology. Cryo-EM maps and a deposited crystal structure provide a template that other groups can mine for the emerging rules of glue-induced neosubstrate recognition.

Caveats remain, as they always do at the preclinical-to-clinical boundary. The efficacy data come from xenograft and cell-line models rather than patients, and the long-term consequences of chronically eliminating ALK, which has physiological roles outside cancer, will need careful toxicological evaluation. The authors note that their work was conducted by employees of Triana Biomedicines, with a patent covering TRI-611 filed by the company, and the compound’s clinical profile will ultimately be decided in human trials. Still, the bar this molecule clears is high: potent, selective, orally bioavailable, brain-penetrant degradation of a validated oncogenic driver, active against the resistance mutations that defeat today’s best drugs, and compatible with rational combinations. If the clinical experience mirrors the preclinical one, TRI-611 could mark the moment molecular glue degraders graduated from the lab bench to a front-line role against gene-fusion-driven cancers, and the strategy of degrading rather than inhibiting oncogenic kinases may rapidly expand beyond ALK.

Subject of Research: A selective, brain-penetrant molecular glue degrader of ALK fusion proteins for ALK-positive non-small-cell lung cancer

Article Title: TRI-611, a selective, brain-penetrant molecular glue degrader of ALK

Article References: Conery, A. R., La, D. S., Alekseyenko, A. A., Marcoux, D., Bart, A. G., Harlow, M. L., Arsenault, P. R., Cantone, N. R., Casaubon, R. L., Constan, A., Kamadurai, H. B., Medikonda, A. P., Nunes, D. E., Szeto, H., Wigle, T. J., Yu, M., Zagulyaeva, A., Zarate, C. M., Highfield, L., … Palombella, V. J. (2026). TRI-611, a selective, brain-penetrant molecular glue degrader of ALK. Nature. https://doi.org/10.1038/s41586-026-10998-3

Image Credits: AI Generated

DOI: 10.1038/s41586-026-10998-3

Keywords: ALK, TRI-611, molecular glue degrader, non-small-cell lung cancer, targeted protein degradation, cereblon, EML4-ALK, TKI resistance, brain penetration, lorlatinib, oncogenic fusion, drug discovery

Traditional inhibitors function by binding to mutant KRAS proteins and obstructing their activity, but this method often falls short as cancer cells evolve mechanisms to circumvent inhibition and resume proliferative signaling. Addressing this limitation, the new study pivots towards inducing the selective degradation of the mutant KRAS protein itself, rather than merely inhibiting its function. This strategy leverages Proteolysis Targeting Chimeras (PROTACs), an innovative drug class designed to co-opt the cell’s intrinsic protein degradation machinery, effectively “tagging” the oncogenic protein for proteasomal destruction.

However, no current PROTACs can directly engage KRAS^G12V, posing a significant challenge. To overcome this, the research team ingeniously engineered lung cancer cells to express KRAS^G12V appended with a molecular tag amenable to novel PROTACs developed in collaboration with chemical biology experts at IRB Barcelona. This innovative tagging allowed the precise recruitment of the degradation system, resulting in efficient elimination of the mutant KRAS protein in vivo.

Employing genetically modified mouse models harboring these tagged KRAS^G12V proteins, the researchers observed remarkable tumor regression upon PROTAC treatment. The lung adenocarcinomas regressed substantially, highlighting the tumor cells’ profound dependency on continuous KRAS^G12V signaling for survival and proliferation. This response was more robust and durable compared to outcomes previously reported with conventional KRAS inhibitors, suggesting that targeted proteolysis could represent a superior therapeutic avenue.

Intriguingly, the study also delineated the immune landscape following KRAS degradation. Although an increase in immune cell infiltration within treated tumors was documented, parallel experiments in immunodeficient mice confirmed that the initial tumor regression was predominantly driven by direct cancer cell-autonomous mechanisms rather than the immune system. This insight emphasizes the fundamental cytotoxic potential of mutant KRAS degradation, independent of adaptive immune activation.

Delving deeply into the mechanisms of acquired resistance, the scientists uncovered a resistance paradigm distinct from that encountered with kinase inhibitors. Instead of mutations within KRAS itself or reactivation of downstream oncogenic pathways, resistant tumors exhibited alterations in the cellular proteostasis machinery. These modifications impaired the effectiveness of the proteasomal degradation system, effectively sabotaging the molecular machinery required to dismantle mutant KRAS, thereby allowing the tumor cells to evade destruction.

This distinct resistance mechanism highlights an evolutionary pressure on tumors to preserve KRAS dependence while simultaneously overcoming the novel therapeutic approach. By dysregulating protein degradation pathways, cancer cells develop an unexpected mode of resistance, underscoring the complexity of targeted proteolysis as a therapeutic modality and the necessity for combination strategies or next-generation PROTACs that can circumvent this escape route.

The conception and execution of this work are the result of a highly collaborative endeavor, integrating expertise from molecular biology, chemical synthesis, and cancer pharmacology across institutions including IRB Barcelona, Centro de Investigación del Cáncer, University of Salamanca, University of Navarra, Catalan Institute of Oncology, University of Liège, University of Turin, CIBERONC, and University of Barcelona. The interdisciplinary nature of this research reinforces the value of collaborative networks in tackling the formidable challenge of KRAS-driven malignancies.

From a therapeutic development perspective, these findings signal the dawn of a new era in targeted cancer therapies. While KRAS inhibitors revolutionized treatment paradigms, the advent of targeted protein degradation represents a paradigm shift with potential transformative impacts on clinical outcomes. The prospect of deploying sequential or combinatorial regimens, integrating KRAS inhibition with degradation, could potentiate tumor control and circumvent the resistance that plagues monotherapy approaches.

Moreover, the tailored strategy of tagging mutant KRAS not only facilitates in vivo functional studies of KRAS degradation dynamics but also establishes a versatile platform to explore PROTAC efficacy against other oncogenic drivers traditionally deemed “undruggable.” This platform empowers future preclinical investigations and accelerates the translation of proteolysis-based therapeutics into clinical settings for diverse cancer types.

Support for this pioneering research was generously provided by the Spanish Ministry of Science and Innovation, the European Research Council (ERC), the Spanish Association Against Cancer (AECC), Generalitat de Catalunya, the European Union’s NextGenerationEU program, “la Caixa” Foundation, and Farmaindustria. Their commitment underscores the critical societal imperative of advancing cancer research toward curative therapies.

In summary, the strategic targeting of mutant KRAS through induced degradation via PROTAC technology represents a compelling advance, combining molecular innovation with therapeutic promise. This elegant approach not only deepens understanding of lung adenocarcinoma biology but also charts new directions for combating resistance, potentially heralding a future where devastating KRAS-driven cancers can be durably controlled or eradicated.

Subject of Research: Targeted degradation of mutant KRAS in lung adenocarcinoma using PROTAC technology and investigation of resistance mechanisms in vivo.

Article Title: Targeted KRASG12V degradation in vivo elicits lung adenocarcinoma regression with subsequent relapse from dysregulated proteolysis

News Publication Date: 27 May 2026

Image Credits: IRB Barcelona

Keywords: Lung cancer, KRAS mutation, oncogene, targeted protein degradation, PROTACs, drug resistance, lung adenocarcinoma, immunotherapy, cancer treatment, proteolysis, in vivo study, molecular tag

The concept of using PROTACs (Proteolysis Targeting Chimeras) in cancer treatment has generated immense interest in the scientific community. PROTACs represent a cutting-edge technology that harnesses the body’s ubiquitin-proteasome system to selectively degrade specific proteins implicated in cancer progression. ARV-825, a novel PROTAC, has shown promise in targeting the BET (bromodomain and extraterminal) family of proteins, which play a crucial role in tumor growth and survival. However, one major limitation that has hindered its clinical application is the effective delivery of ARV-825 across the BBB.

Recognizing the limitations of traditional administration routes, the researchers focused on developing a nanosuspension that incorporates permeability enhancers, allowing the therapeutic agent to cross the BBB more efficiently. This groundbreaking formulation leverages advanced nanotechnology to create a nanoscale suspension that increases the drug’s surface area, promoting its absorption in the intestinal tract and subsequent entry into the systemic circulation. By employing biocompatible and biodegradable materials, the researchers ensured that the formulation not only enhances the therapeutic effects of ARV-825 but also minimizes potential toxicity.

In laboratory tests, the oral nanosuspension demonstrated enhanced solubility and stability compared to conventional formulations. The researchers conducted a series of experiments to evaluate the pharmacokinetics of the nanosuspension, which revealed promising results. The oral administration of the formulation led to significantly higher plasma concentrations of ARV-825 compared to its traditional counterparts. These findings suggest that the permeability-enhanced nanosuspension could potentially translate to more robust therapeutic outcomes in glioblastoma patients.

Another critical aspect of this research involves the safety profile of the new formulation. While enhancing drug permeability is essential for efficacy, it is equally crucial to ensure that such modifications do not compromise safety. The team conducted extensive preclinical safety assessments, employing various animal models to evaluate potential adverse effects. Early results indicate that the formulation is well-tolerated, with no significant signs of toxicity observed in the test subjects. This safety assurance lays the groundwork for future clinical trials, where the efficacy and tolerability of the nanosuspension will be assessed in human participants.

The innovative combination of PROTAC technology with advanced nanotechnology has the potential to herald a new era in glioblastoma treatment. By enhancing the delivery of ARV-825, the researchers are targeting the root of the problem: the efficiency of drug delivery to brain tissues. This aspect is particularly crucial given the limited treatment options available for glioblastoma, which often results in poor patient outcomes. The formulation optimistically represents a significant advancement that could not only improve survival rates but also enhance the quality of life for patients struggling with this aggressive cancer.

Furthermore, the approach of combining a PROTAC with a specialized oral delivery system might also inspire research into similar therapies for other types of cancers. As studies continue to reveal more about the molecular underpinnings of various malignancies, the hope is that similar innovations can be adapted to address different therapeutic challenges across oncology.

The findings from Patel, Yadav, and Dukhande also raise exciting prospects for personalized medicine in oncology. As healthcare increasingly moves towards individualized treatment strategies, the ability to enhance drug delivery systems could allow for tailored therapeutic regimens that maximize efficacy based on a patient’s specific tumor characteristics. This personalization may eventually result in more effective and fewer side-effect treatment options, a long-sought goal in the cancer research community.

Collaboration between researchers, pharmaceutical industries, and regulatory bodies will be essential as this research moves toward clinical applications. The transition from bench to bedside is fraught with challenges, yet the significance of this work cannot be overstated. Ensuring sufficient funding, support for advanced manufacturing processes, and adherence to rigorous regulatory standards will facilitate the development of this promising therapeutic strategy.

As public awareness increases around the urgency of brain cancer research, studies like this one shine a light on the critical need for innovative solutions. Engaging with patient advocacy groups and educational initiatives will help disseminate knowledge and foster broader support for promising research endeavors. Such efforts create a conducive environment for innovative scientific exploration, leading to potentially transformative solutions in cancer treatment.

In conclusion, the research conducted by Patel and team makes substantial contributions to the ongoing battle against glioblastoma. The exploration of permeability-enhanced nanosuspension for the oral delivery of ARV-825 PROTAC not only offers hope for improved treatment outcomes but also sets the foundation for potentially groundbreaking developments in cancer therapy. As the scientific community continues to grapple with the complexities of drug delivery and cancer biology, collaborative efforts driving this innovative research could reshape the future of glioblastoma treatment and beyond.

The implications of this study extend beyond glioblastoma, highlighting the versatility of PROTAC technology and advanced delivery systems. By successfully engineering a formulation that addresses the critical challenge of drug delivery, researchers are poised to broaden the scope of PROTAC applications. Ultimately, this work paves the way for a new chapter in the fight against cancer where better-targeted therapies and innovative treatment strategies may become the norm rather than the exception.

The research undertaken by Patel, Yadav, and Dukhande serves as a crucial reminder of the impact that cutting-edge science can have on patient care and treatment modalities. Such innovations can spark hope in patients and their families, showcasing the relentless pursuit of better solutions in the realm of oncology. As clinical trials unfold, the medical community eagerly anticipates the firsthand results of this groundbreaking research.

While the road ahead remains challenging, the potential for improved life-saving therapies in glioblastoma and other malignancies remains rich with possibilities. The increasing integration of nanotechnology with traditional therapeutic approaches may soon bring forth a brighter future for cancer patients worldwide.

Subject of Research: Oral nanosuspension of ARV-825 PROTAC for glioblastoma treatment

Article Title: Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment.

Article References:

Patel, H., Yadav, A., Dukhande, V. et al. Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment.
J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00771-5

Image Credits: AI Generated

DOI: 10.1007/s40005-025-00771-5

Keywords: Glioblastoma, PROTAC, ARV-825, Nanosuspension, Drug delivery